Summary

• WhiteLab Genomics has closed a $26 million Series B led by AVP.
• Its ALFRED platform designs delivery systems and genetic payloads before experimental and in vivo validation.
• Funding will expand work across viral and nonviral delivery technologies and commercial activity in Europe, North America and Asia.

Paris and Boston based WhiteLab Genomics has raised $26 million to expand a genomic medicine platform that combines AI design with laboratory and in vivo testing, directing more capital towards the point where computational predictions encounter biological reality.

AVP led the Series B, with new investors Yaday Health and Blast Club joining Omnes Capital and Debiopharm Innovation Fund. WhiteLab plans to expand validation programmes, develop additional delivery technologies and increase commercial activity across Europe, North America and Asia.

The company uses its ALFRED platform to design elements of genomic medicines, including the vehicles that deliver genetic material and the payloads intended to act once they reach a target cell. Candidate designs then move into experimental work rather than being treated as useful simply because a model ranked them highly.

Delivery remains one of the harder problems in genomic medicine. A therapeutic construct can be biologically interesting without becoming clinically useful if it cannot reach the right tissue, enter enough cells or produce the intended activity without unacceptable effects elsewhere.

Design narrows the search, experiments decide

WhiteLab initially concentrated on adeno associated viruses, or AAVs, which can be engineered to carry genetic material into cells. The company says work with the Paris Brain Institute has shown potential for AI designed AAVs in brain delivery, an area where biological barriers make effective targeting particularly difficult.

ALFRED is intended to reduce the number of candidates that researchers need to explore experimentally by using biological information and computational methods to identify designs more likely to meet defined requirements. The process does not remove the need for physical validation; it changes which candidates reach that stage.

The Series B will broaden that work into nonviral delivery systems including lipid nanoparticles and into synthetic promoters, genetic control elements that influence where and when a therapeutic gene becomes active. Those additions move WhiteLab beyond optimisation of a single delivery vehicle towards a larger combination of delivery and payload design.

That matters because the components interact. Improving a vector’s ability to reach a tissue does not guarantee that the genetic payload will behave appropriately once delivered, while an effective payload has little value if the delivery system cannot place it in the relevant cells.

WhiteLab describes the resulting designs as experimentally validated bio assets, which can be developed with pharmaceutical partners or advanced further before a commercial partnership. The funding is therefore supporting a development platform rather than one late stage medicine approaching the market.

AI investment meets a stricter evidence boundary

Biological AI has attracted large amounts of capital because computational systems can search spaces that are too large to test exhaustively in a laboratory. Models can suggest proteins, vectors or other biological constructs in volumes that conventional experimental programmes could never examine one by one.

Biology still determines which of those suggestions survive. Cells, tissues and whole organisms contain interactions that may not be represented fully in a training dataset, while safety and delivery constraints can eliminate candidates that look promising computationally.

WhiteLab’s financing puts that validation boundary at the centre of its next phase. More in vivo work is slower and more expensive than running another model, yet it produces the evidence needed to decide whether an AI designed construct warrants further therapeutic development.

The company’s focus on delivery also differentiates it from other biological AI businesses centred primarily on target discovery or large biological datasets. Techopia recently covered Basecamp Research’s financing around AI driven biological discovery; WhiteLab’s current round concerns the engineering and experimental validation of genomic delivery systems and payloads rather than the same development.

Commercial expansion will proceed alongside the science. Operating from Paris and Boston gives WhiteLab access to two large life sciences markets, while the new round is intended to deepen activity across North America, Europe and Asia.

The board is changing as well, with François Robinet of AVP and Daniel Teper of Yaday Health joining for the next stage of growth. Their arrival reflects the transition from a smaller technical company towards one expected to manage more programmes and partnerships in parallel.

Claims that the platform can reduce time, cost or experimental trial and error should remain tied to WhiteLab’s own proposition rather than treated as established outcomes across drug development. The company has not presented the Series B as proof that AI has solved genomic medicine delivery.

Instead, the financing gives it more capacity to run the experiments that can falsify its own computational choices. That is a more demanding measure of progress than the number of designs a model can generate, but it is also the one that ultimately determines whether those designs have value as medicines.